Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

China approves COVID-19 vaccine from Sinopharm

By Brian Buntz | December 31, 2020

SinopharmChinese health authorities have authorized a SARS-CoV-2 vaccine from state-owned Sinopharm (OTCMKTS: SHTDY). The vaccine has an efficacy of 79% based on an interim analysis of a Phase 3 study. 

China plans to distribute the BBIBP-CorV vaccine to citizens at no cost and distribute it to other countries that test Chinese vaccine candidates. 

The country has already begun mass vaccination, granting emergency use of the vaccine to essential workers, students and diplomats. 

Sinopharm chairman Liu Zingzhen stated on Nov. 20 that more than 66,000 Chinese recipients of the vaccine had traveled abroad without contracting COVID-19. 

The 79% efficacy rate, however, was lower than the 86% efficacy researchers in the United Arab Emirates reported on Dec. 9 in Phase 3 interim analysis for the Sinopharm vaccine. 

Sinopharm and its domestic competitor Sinovac employ inactivated coronaviruses in their vaccines. The downside to that approach is biosecurity, as it requires working with large amounts of coronavirus samples. 

To create the vaccine, Beijing Institute scientists procured three COVID-19 strains from hospitalized patients, selecting a variant that grew in monkey kidney cells within a bioreactor. They then inactivated the virus with the chemical beta-propiolactone

While the approach has been commonly used for decades, other prominent vaccine developers such as Moderna (NSDQ:MRNA) and Pfizer (NYSE:PFE) and partner BioNTech have opted to use mRNA technology. In contrast, the Oxford-AstraZeneca (LON:AZN) vaccine uses a chimpanzee adenovirus-vector. 

Tell Us What You Think! Cancel reply

Related Articles Read More >

Norway investigating deaths of 23 individuals who received COVID-19 vaccine
Pharma image
Here’s what molecular shape can tell you about pharma innovation
Remdesivir
3 notable types of innovative drugs from 2020
Phastar
Phastar wins investment from Charterhouse Capital Partners

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards